Detalhe da pesquisa
1.
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
Cancer
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38752572
2.
A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression.
J BUON
; 21(3): 698-708, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27569093
3.
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
JCO Glob Oncol
; 10: e2300285, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38206277
4.
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
BioDrugs
; 37(3): 433-440, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36881323
5.
Hereditary Breast Cancer in Romania-Molecular Particularities and Genetic Counseling Challenges in an Eastern European Country.
Biomedicines
; 11(5)2023 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37239058
6.
Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.
Int J Environ Res Public Health
; 19(7)2022 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35409996
7.
Advancing Breast Cancer Advocacy in Eastern Europe and Central Asia: Findings From Women's Empowerment Cancer Advocacy Network (WE CAN) Summits.
JCO Glob Oncol
; 7: 585-592, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891477
8.
Circulating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A review.
Clujul Med
; 89(2): 203-11, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27152069